Phase II Clinical Study of Radium-223 Chloride (BAY 88-8223) in Japanese Patients With Symptomatic Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [31] Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA)
    Miller, K.
    Sartor, A. O.
    Heinrich, D.
    Helle, S., I
    O'Sullivan, J. M.
    Fossa, S. D.
    Chodacki, A.
    Demkow, T.
    Logue, J. P.
    Seke, M.
    Widmark, A.
    Johannessen, D. C.
    Nilsson, S.
    Hoskin, P.
    Solberg, A.
    James, N. D.
    Syndikus, I
    Vogelzang, N. J.
    O'Bryan-Tear, C. G.
    Shan, M.
    Parker, C.
    ONKOLOGIE, 2012, 35 : 238 - 239
  • [32] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A-K
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 59
  • [33] Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study
    Morris, Michael J.
    Hammers, Hans J.
    Sweeney, Christopher
    Antonarakis, Emmanuel S.
    Cho, Steve Y.
    Pandit-Taskar, Neeta
    Jacene, Heather
    Bloma, Marianne
    Aksnes, Anne-Kirsti
    O'Bryan-Tear, C. Gillies
    Carrasquillo, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases
    Nilsson, Sten
    Sartor, A. Oliver
    Bruland, Oyvind S.
    Fang, Fang
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [35] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A. K.
    Parker, C.
    ONKOLOGIE, 2013, 36 : 17 - 18
  • [36] Clinical experience of using the radium-223 in patients with bone metastasis of castration-resistant prostate cancer
    Yurmazov, Z. A.
    Usynin, E. A.
    Medvedeva, A. A.
    Polyakov, A. A.
    Lushnikova, N. A.
    Chernov, V., I
    Spirina, L., V
    ONKOUROLOGIYA, 2022, 18 (01): : 70 - 76
  • [37] Efficacy and Safety of Radium-223 Dichloride in the Treatment of Patients with Castration-Resistant Prostate Cancer with Bone Metastases
    Sanchez Lopez, Hector
    GACETA MEXICANA DE ONCOLOGIA, 2016, 15 : 1 - 2
  • [38] Treatment of patients with castration-resistant prostate cancer and bone metastases with radium-223: A single institution experience
    Devarakonda, Srinivas S.
    Skweres, Justin
    Nair, Binu Sivaraman
    Dhawan, Manish
    Takalkar, Amol
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review
    Cursano, M. C.
    Iuliani, M.
    Casadei, C.
    Stellato, M.
    Tonini, G.
    Paganelli, G.
    Santini, D.
    De Giorgi, U.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 146
  • [40] Efficacy and tolerance of radium-223 dichloride in patients treated for castration-resistant prostate cancer with bone metastases
    Awoudou, C.
    Bathily, E. H. A. L.
    Djigo, M. S.
    Ndong, B.
    Mbodj, M.
    Paulus, P.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2024, 48 (03): : 150 - 157
12345